{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:21:24Z","timestamp":1791426084526,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/sj.bjc.6604382","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T09:51:40Z","timestamp":1211968300000},"page":"1736-1740","source":"Crossref","is-referenced-by-count":168,"title":["Risks and benefits of bisphosphonates"],"prefix":"10.1038","volume":"98","author":[{"given":"R E","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"issue":"8","key":"BF6604382_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","volume":"137","author":"American Dental Association Council on Scientific Affairs","year":"2006","unstructured":"American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137 (8): 1144\u20131150","journal-title":"J Am Dent Assoc"},{"issue":"17","key":"BF6604382_CR2","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"American Society of Clinical Oncology","year":"2007","unstructured":"American Society of Clinical Oncology (2007) Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (17): 2464\u20132472","journal-title":"J Clin Oncol"},{"key":"BF6604382_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809\u20131822","journal-title":"N Engl J Med"},{"key":"BF6604382_CR4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","volume":"17","author":"M Botteman","year":"2006","unstructured":"Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M (2006) Cost-effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 17: 1072\u20131082","journal-title":"Ann Oncol"},{"key":"BF6604382_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59\u201369, doi:10.1093\/jnci\/dji002","journal-title":"J Natl Cancer Inst"},{"key":"BF6604382_CR6","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","volume":"20","author":"MJ Clemons","year":"2006","unstructured":"Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 20: 4895\u20134900","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"BF6604382_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","volume":"31","author":"P Clezardin","year":"2005","unstructured":"Clezardin P (2005) Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31 (Suppl 3): 1\u20138, 134s-6230s","journal-title":"Cancer Treat Rev"},{"issue":"suppl. 4","key":"BF6604382_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9 (suppl. 4): 14\u201327","journal-title":"Oncologist"},{"issue":"20 suppl","key":"BF6604382_CR9","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12 (20 suppl): 6243\u20136249","journal-title":"Clin Cancer Res"},{"key":"BF6604382_CR10","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925\u20134935","journal-title":"J Clin Oncol"},{"issue":"8","key":"BF6604382_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18 (8): 1023\u20131031","journal-title":"Osteoporos Int"},{"key":"BF6604382_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ncponc0688","volume":"4","author":"CR Dunstan","year":"2007","unstructured":"Dunstan CR, Felsenberg D, Seibel MJ (2007) Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4: 42\u201355, (17183355)","journal-title":"Nat Clin Pract Oncol"},{"key":"BF6604382_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25: 820\u2013828","journal-title":"J Clin Oncol"},{"key":"BF6604382_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","volume":"10","author":"V Guarneri","year":"2005","unstructured":"Guarneri V, Donati S, Nicolini M, Giovannelli S, D\u2019Amico R, Conte PF (2005) Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10: 842\u2013848, (16314295)","journal-title":"Oncologist"},{"key":"BF6604382_CR15","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042\u20134057","journal-title":"J Clin Oncol"},{"key":"BF6604382_CR16","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1200\/jco.2006.24.18_suppl.8528","volume":"24","author":"AO Hoff","year":"2006","unstructured":"Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, Sayegh GG, Johnson MM, Gagel RF, Hortobagyi GN (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol ASCO Annual Meeting Proceedings Part I 24, No 18S (June 2006 Supplement) 8528","journal-title":"J Clin Oncol"},{"issue":"10","key":"BF6604382_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 22 (10): 1479\u20131491","journal-title":"J Bone Min Res"},{"key":"BF6604382_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ctrv.2005.01.008","volume":"31","author":"J Lester","year":"2005","unstructured":"Lester J, Dodwell D, McCloskey E, Coleman R (2005) The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31: 115\u2013142","journal-title":"Cancer Treat Rev"},{"key":"BF6604382_CR19","doi-asserted-by":"crossref","unstructured":"Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D, Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: one-year results from the ARIBON study. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, Illinois J Clin Oncol 25 (18S): Abstract 553","DOI":"10.1200\/jco.2007.25.18_suppl.553"},{"key":"BF6604382_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01674812","volume":"7","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Christiansen C, Einhorn TA, McKay Hart D, Ljunghall S, Mautalen CA, Meunier PJ, Morii H, Mundy GR, Rapado A, Stevenson J (1997) Consensus development statement: who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7: 1\u20136","journal-title":"Osteoporos Int"},{"key":"BF6604382_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofacial Surgery 61: 1115\u20131118","journal-title":"J Oral Maxillofacial Surgery"},{"key":"BF6604382_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00019053-200826030-00007","volume":"26","author":"K McKeage","year":"2008","unstructured":"McKeage K, Plosker GL (2008) Zoledronic acid. A pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 26: 251\u2013268","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"BF6604382_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 (9): 1038\u20131042","journal-title":"J Clin Oncol"},{"key":"BF6604382_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ijc.20602","volume":"113\/3","author":"HL Neville-Webbe","year":"2005","unstructured":"Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113\/3: 364\u2013371","journal-title":"Int J Cancer"},{"key":"BF6604382_CR25","unstructured":"Novartis (2005) Background Information for Oncologic Drugs Advisory Committee Meeting March 4, 2005, Novartis internal document 2005"},{"key":"BF6604382_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1097\/01.ju.0000116777.94426.60","volume":"171","author":"SD Reed","year":"2004","unstructured":"Reed SD, Radeva JL, Glendinning GA, Saad F, Schulman KA (2004) Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in prostate cancer. J Urol 171: 1537\u20131542","journal-title":"J Urol"},{"issue":"20 Pt 2","key":"BF6604382_CR27","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12 (20 Pt 2): 6222","journal-title":"Clin Cancer Res"},{"key":"BF6604382_CR28","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100: 2613\u20132621","journal-title":"Cancer"},{"key":"BF6604382_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL (2004) Osteonecrosis of the jaws asssociated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"key":"BF6604382_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","volume":"102","author":"SL Ruggiero","year":"2006","unstructured":"Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 433\u2013444 (16997108)","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"BF6604382_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"BF6604382_CR32","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008\u20132012","journal-title":"J Urol"},{"issue":"suppl 1","key":"BF6604382_CR33","first-page":"S37","volume":"106","author":"C Van Poznak","year":"2007","unstructured":"Van Poznak C, Hannon RA, Clack G, Campone M, Mackey JR, Apffelstaedt J, Eastell R (2007) The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12 month analysis. Breast Cancer Res and Treat 106 (suppl 1): S37 (abs 502)","journal-title":"Breast Cancer Res and Treat"},{"key":"BF6604382_CR34","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jnci\/djm025","volume":"99","author":"GS Wilkinson","year":"2007","unstructured":"Wilkinson GS, Kuo Y-F, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99: 1016\u20131024","journal-title":"J Natl Cancer Inst"},{"key":"BF6604382_CR35","first-page":"CD002068","volume":"2","author":"R Wong","year":"2002","unstructured":"Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2: CD002068","journal-title":"Cochrane Database Syst Rev"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604382","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:33:07Z","timestamp":1684398787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BF6604382"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604382","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}